The results presented at the NextGen Biomed 2025 conference by Oxford Global in London from March 12-14 demonstrate that inhibition of VPS34 in mice activates the immune system and enhances the treatment response to STING agonists. This discovery opens new possibilities for treatment combinations that could lead to improved therapeutic responses in immunotherapies that rely on the patient's own immune system, such as anti-PD-1/PD-L1 antibodies. The presentation is titled “Improving STING agonist in-vivo efficacy in mice by combination with VPS34 inhibitors.”

The presentation at the Tumour Models Summit Nordics in Stockholm from April 9-10 will focus on the tumor models used in the program. This presentation is titled “Using syngeneic models to understand the molecular pathways leading to improved STING therapy using VPS34 inhibitors.” At both conferences, Sprint Bioscience will be represented by Santiago Parpal, Principal Scientist, Tumor Biology & Therapeutics.

"We have shown that inhibition of VPS34 can enhance the effect of immune-activating checkpoint inhibitors and STING agonists, which is very promising. The need for improved treatment responses in immuno-oncology is significant, as the effectiveness varies between patients and often diminishes over time. By presenting our previously published results at scientific conferences, we spread the knowledge about our programs and strengthen our already established reputation," says Johan Emilsson, CEO of Sprint Bioscience.